Clinical Trials Directory
Children with IBS will eat a food called fructans to see if it makes their symptoms worse. If it does, they will be placed into one of three groups. One group will get a fake treatment called a placebo. The other two groups will get a fiber called psyllium in different amounts based on their age. They will take this for two weeks. During this time, they will check their poop and write down how they feel. The whole study may last up to three months.
We created this registry to have a database of healthy people who are interested in participating in research about lung health and breathing. We will use this registry to reach out to people and notify them about research studies in which they might be interested.
We maintain this registry to have a database of people with any type of lung or breathing disorder who are interested in participating in research about their lung condition.
We are doing this study to collect information about the clinical performance of the PulseSelect® Pulsed Field Ablation (PFA) System. The PFA system was recently approved by the FDA as a treatment for both paroxysmal and persistent atrial fibrillation (AF). We want to learn more about how well it works for AF patients now that it is a widely available option. We will assess how well it improves symptoms for people who who have persistent AF that has lasted less than one year, or have experienced episodes of paroxysmal atrial fibrillation, or have persistent or paroxysmal atrial fibrillation that is not controlled by medication, or have symptoms from their persistent or paroxysmal atrial fibrillation.
We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.
If you choose to join this study, we will ask you questions about:
- Your life at home
- Your life at school
- Your medical needs
We are doing this study to find the most effective, safe dose of an experimental drug called quizartinib (the study drug) for people with acute myeloid leukemia (AML) who do not have a FLT3-ITD mutation and who have not completed any treatment for their disease.